HKeyBio Slashes CRO Pricing for NHP Studies Despite Supply Constraints

• HKeyBio, a preclinical CRO, has reduced pricing for non-human primate (NHP) autoimmune models despite a global monkey shortage.

• The move is intended to support biopharma clients and increase study volume during ongoing funding and supply challenges.

HKeyBio announced it is reducing prices for its non-human primate (NHP) autoimmune disease models, positioning the move as a counter-cyclical strategy amid a global shortage of research monkeys. The decision contrasts with broader market trends, where limited supply has driven increased costs for preclinical CRO services relying on NHP models. 

The company said the pricing adjustment is intended to support pharmaceutical and biotechnology clients facing both supply constraints and tighter funding conditions. By lowering costs, HKeyBio aims to maintain access to high-fidelity preclinical models that are critical for translational research in autoimmune and inflammatory diseases. 

As a CRO specializing in NHP-based preclinical pharmacology, HKeyBio provides services including efficacy evaluation, PK/PD modeling, and biomarker analysis. The company indicated that increasing study volume during this period will allow it to expand its dataset of translational biomarkers and disease endpoints across autoimmune indications. 

From a CRO market perspective, the strategy reflects a shift toward long-term positioning rather than short-term margin optimization. By enabling more studies during a constrained supply environment, HKeyBio aims to strengthen its scientific platform and broaden its presence among emerging biopharma clients navigating funding pressures. 

“By increasing the volume of NHP preclinical pharmacology studies during this period, HKEYBIO aims to accumulate more validating translational biomarkers experience and disease phenotypic endpoints.”

HKeyBio Official Statement